Drug-Induced Hypersensitivity Syndrome

Comprehensive Clinical Guide: Drug-Induced Hypersensitivity Syndrome (DiHS/DRESS)

Drug-Induced Hypersensitivity Syndrome (DiHS), more commonly referred to in modern clinical literature as DRESS Syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms), represents one of the most complex, life-threatening, and diagnostic-heavy challenges in internal medicine, dermatology, and clinical immunology. It is a severe, idiosyncratic, multi-organ hypersensitivity reaction that typically emerges between two to eight weeks after the initiation of a culprit medication.

Unlike common maculopapular drug eruptions, DRESS is characterized by a prolonged latency period, systemic inflammation, hematologic abnormalities, and significant potential for long-term morbidity, including the development of autoimmune sequelae.

1. Etiology and Pathophysiology: The Molecular Landscape

The pathogenesis of DRESS is multifactorial, involving a complex interplay between drug metabolism, immunological activation, and viral reactivation.

The Delayed Hypersensitivity Mechanism

DRESS is categorized as a Type IVb hypersensitivity reaction (T-cell mediated). The process begins when a "culprit" drug or its reactive metabolite binds to human leukocyte antigen (HLA) molecules on antigen-presenting cells (APCs). This stimulates a massive expansion of drug-specific CD4+ and CD8+ T-cells.

Viral Reactivation Theory

A hallmark of DRESS—which distinguishes it from other severe cutaneous adverse reactions (SCARs) like Stevens-Johnson Syndrome (SJS)—is the sequential reactivation of herpesviruses. The "DRESS cascade" typically follows this pattern:
1. HHV-6 (Human Herpesvirus 6) Reactivation: Occurs in approximately 70% of cases.
2. EBV (Epstein-Barr Virus) and CMV (Cytomegalovirus): Often follow the HHV-6 surge.
3. Clinical Manifestation: The reactivation of these viruses contributes to the severity of the systemic symptoms, including hepatitis and lymphadenopathy, even after the drug is discontinued.

Genetic Predisposition

Individual susceptibility is heavily linked to specific HLA alleles. For example:
* Carbamazepine: Associated with HLA-B15:02 (in Asian populations) and HLA-A31:01.
* Allopurinol: Strongly associated with HLA-B*58:01.

2. Clinical Presentation and Staging

The clinical presentation of DRESS is often deceptive, beginning with flu-like symptoms (fever, malaise) that mimic viral infections, before the characteristic cutaneous eruption appears.

The RegiSCAR Scoring System

Clinicians utilize the RegiSCAR (Registry of Severe Cutaneous Adverse Reactions) criteria to confirm a diagnosis. A score of >5 indicates "Definite" DRESS.

Clinical Staging

1. Prodromal Phase (Weeks 2-6): Fever, lymphadenopathy, and pharyngitis.
2. Acute Phase (Days 7-14): Diffuse maculopapular rash, facial edema, and systemic organ involvement.
3. Recovery Phase (Weeks to Months): Gradual resolution, though often complicated by autoimmune conditions.

3. Diagnostic Investigation and Differential Diagnosis

Key Diagnostic Tests

• Complete Blood Count (CBC): Essential for monitoring eosinophilia and atypical lymphocytosis.
• Liver Function Tests (LFTs): ALT/AST elevation is common and indicates hepatitis.
• Renal Panel: Serum creatinine and BUN to monitor interstitial nephritis.
• Viral PCR: Testing for HHV-6, EBV, and CMV DNA in plasma.
• Skin Biopsy: Typically shows dense perivascular lymphocytic infiltrates with eosinophils.

Differential Diagnosis

It is critical to distinguish DRESS from other life-threatening dermatological emergencies:
* SJS/T Characterized by epidermal detachment and necrosis; DRESS is characterized by infiltration and systemic inflammation.
* Acute Generalized Exanthematous Pustulosis (AGEP): Rapid onset (hours to days) with sterile pustules.
* Viral Exanthems: Measles, rubella, or primary HIV infection.
* Lymphoma: Specifically cutaneous T-cell lymphoma, which can mimic the clinical appearance of DRESS.

4. Risks, Side Effects, and Long-Term Prognosis

The "Hidden" Risks

DRESS is not merely a skin condition; it is a systemic inflammatory state. The most significant risks include:
* Fulminant Hepatitis: The leading cause of death in DRESS patients.
* Myocarditis: Often asymptomatic initially but can lead to sudden heart failure.
* Autoimmune Sequelae: Post-DRESS patients are at an increased risk for developing Type 1 Diabetes, Graves’ disease, and systemic lupus erythematosus months after the resolution of the initial reaction.

Management Strategy

1. Immediate Cessation: Discontinue all non-essential medications immediately.
2. Systemic Corticosteroids: The gold standard for management, usually starting at 0.5–1.0 mg/kg/day of prednisone.
3. Supportive Care: Fluid resuscitation, electrolyte balancing, and topical steroids for skin pruritus.
4. Tapering: Must be done very slowly (over 6-8 weeks) to prevent rebound of the systemic inflammatory response.

5. Massive FAQ Section: Frequently Asked Questions

1. How long does the rash last in DRESS syndrome?

The rash can persist for several weeks, even after the culprit drug is stopped. Unlike simple drug allergies that clear in days, DRESS has a prolonged recovery trajectory.

2. Is DRESS the same as Stevens-Johnson Syndrome (SJS)?

No. While both are severe drug reactions, SJS involves rapid skin necrosis and mucosal involvement. DRESS is characterized by systemic involvement (liver, kidneys, blood) and a much longer latency period.

3. Which drugs are the most common culprits for DRESS?

Anticonvulsants (carbamazepine, phenytoin, lamotrigine), allopurinol, sulfonamides, and certain antibiotics (vancomycin, minocycline) are the most frequent triggers.

4. Can I ever take the offending drug again?

Absolutely not. Re-exposure to the culprit drug—or even drugs in the same chemical class—can trigger a fatal reaction.

5. What are "atypical lymphocytes" and why do they matter?

Atypical lymphocytes are activated T-cells that appear in the blood during DRESS. Their presence is a hallmark diagnostic marker for the syndrome.

6. Is DRESS contagious?

No. While viral reactivation (HHV-6) is part of the mechanism, the syndrome itself is an idiosyncratic immune response, not an infectious disease.

7. Does the fever always happen?

Fever is one of the most common early symptoms, occurring in over 90% of cases. It often precedes the rash by several days.

8. What is the mortality rate of DRESS?

The mortality rate is estimated between 5% and 10%, usually due to organ failure or secondary infections resulting from prolonged immunosuppression.

9. Why is a slow steroid taper necessary?

DRESS has a high rate of clinical relapse if steroids are withdrawn too quickly. A slow taper is required to suppress the immune system while the drug is cleared from the body.

10. Can I develop autoimmune diseases after DRESS?

Yes. Studies have shown a significant correlation between DRESS recovery and the subsequent development of autoimmune thyroiditis and other autoimmune disorders, likely due to prolonged immune dysregulation.

6. Clinical Summary Table: Quick Reference

Conclusion

Drug-Induced Hypersensitivity Syndrome (DRESS) is a high-stakes clinical diagnosis that requires a high index of suspicion. Given its ability to mimic common infections and its potential for delayed multi-organ failure, clinicians must prioritize early identification, immediate cessation of the causative agent, and aggressive supportive care. The long-term management of these patients extends beyond the acute phase, requiring vigilance for the development of late-onset autoimmune conditions. As our understanding of pharmacogenomics increases, our ability to prevent these catastrophic events through genetic screening (e.g., HLA testing) will become an essential component of personalized medicine.

Disclaimer: This guide is intended for educational and clinical reference purposes only. It does not replace the judgment of a qualified medical professional. Always consult current clinical guidelines and institutional protocols when managing patients with suspected severe cutaneous adverse reactions.